PDCD1 and neoplasm: As an inhibitor of the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway, the released metformin disrupts the membrane localization of PD-L1, reducing its stability, thereby improving tumor immunotherapy [55].